Royalty Report: Drugs, Therapeutic, Pharmaceuticals – Collection: 6390


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Pharmaceuticals
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 6390

License Grant
This is an Agreement with the  Canadian Licensor regarding financial assistance to be provided by for the development of one or more oral therapeutic products for the treatment of Alzheimer's disease.
Field of Use
Field of Use relates to the healthcare industry.

IPSCIO Record ID: 28033

License Grant
The Licensee and a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to address critical unmet medical needs with disease modifiers, entered into an Agreement with the Licensor regarding financial assistance to be provided for the development of one or more oral therapeutic products for the treatment of Alzheimer's Disease.
Field of Use
The Field of Use relates to the medical industry.

IPSCIO Record ID: 29371

License Grant
The Licensee has a worldwide exclusive License to intellectual property relating to ELND005 (AZD-103) with the undisclosed Licensor, an Alzheimer’s disease researcher at the University of Toronto.
License Property
ELND005 (formerly known as AZD-103), scyllo-inositol, is being investigated as an orally administered treatment for Alzheimer's disease (AD). ELND005 may prevent or inhibit the build up of amyloidal protein in the brains of Alzheimer's disease patients.
Field of Use
The rights granted apply to the healthcare industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.